In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on CytoDyn (CYDY). The company’s shares closed last Tuesday at $2.73.
According to TipRanks.com, Chen is a 4-star analyst with an average return of 9.4% and a 37.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Aerpio Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for CytoDyn.
See today’s analyst top recommended stocks >>
Based on CytoDyn’s latest earnings release for the quarter ending August 31, the company reported a quarterly GAAP net loss of $30.83 million. In comparison, last year the company had a GAAP net loss of $16.16 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, cancer, graft-versus-host disease (GVHD), and PCa test. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.